BioSpace News Archive

Muse Microscopy, Inc., a wholly-owned subsidiary of Smart Health Diagnostics Company, is developing a slide-free diagnostic imaging platform designed to transform the patient’s experience by providing the ability to generate digital tissue images within minutes to send to the pathologist for an immediate read.

Syncromune®, Inc., a clinical-stage biopharmaceutical company dedicated to the development of SYNC-T, an in situ platform combination therapy optimized for solid tumor cancers, announced that it will present late-breaking Phase 1 clinical data at this year’s American Association for Cancer Research Annual Meeting 2024, being held in San Diego, California from April 5 to 10, 2024.

Araris Biotech AG today announced the company will be presenting one abstract and one late-breaking abstract during the American Association for Cancer Research (AACR) Annual Meeting to be held April 5-10, 2024 at the San Diego Convention Center in San Diego, California.

Corbus Pharmaceuticals Holdings, Inc. today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a panel discussion at BMO Capital Markets Inaugural BMO Obesity Summit to be held on March 20, 2024 in New York City, NY.

Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the Barclays 26th Annual Global Healthcare Conference at 1:35 PM ET on Wednesday, March 13, 2024 in Miami.

Replimune Group, Inc. today announced presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024 being held in San Diego, CA from April 5-10, 2024.

Alumis Inc., a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to transform the lives of patients with immune-mediated diseases, today announced an upsized $259M Series C financing.

Auron Therapeutics today announced that the Company will present an overview of its proprietary AURIGIN™ platform and the first preclinical data from its lead program during two poster sessions at the American Association for Cancer Research (AACR) Annual Meeting 2024.

Frontier Medicines Corporation announced new preclinical data for FMC-376, a first-in-class direct dual inhibitor of ON+OFF KRASG12C currently being explored in a Phase 1/2 trial, will be shared at the upcoming American Association for Cancer Research Annual Meeting 2024.

Lipocine Inc. today announced that Dr. Mahesh V. Patel , President and Chief Executive Officer, will participate in a fireside chat and meet with investors at the 36th Annual Roth Conference.